MBI vs NBIX · rev $51.0M vs P/E 45, rev $1.77B
MBIA Inc (MBI) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
MBIA Inc (MBI) is a insurance - specialty company listed on NYSE.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported MBI revenue for 2026-06-30 was $51.0M. Net income was -$85.0M. MBI currently screens at market cap $321.4M.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
MBI currently screens at market cap $321.4M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the MBI and NBIX stock pages for the full models.
Not investment advice.